Thelansis

Non-metastatic castration-sensitive prostate cancer (nmCSPC) constitutes a transient stage of the disease. It emerges with resistance to castration (manifested by testosterone levels falling below 50 ng/mL) after androgen deprivation therapy (ADT). The absence of observable metastases in standard imaging scans characterizes this stage. Simultaneously, there is a gradual increase in prostate-specific antigen (PSA) levels, reaching a minimum of 25% higher than the lowest point (nadir) while starting with a PSA level of ≥ 1.0 ng/mL. This increase must be at least 2 ng/mL and verified by a second reading. Nevertheless, the progression of this condition into metastatic disease is a complex process that is not yet fully comprehended. Most individuals diagnosed with non-metastatic castration-resistant prostate cancer (nmCRPC) do not exhibit symptoms or experience only minor ones due to localized treatment effects. In cases where the PSA doubling time is short (< 10 months) and initial PSA ...